Reduction of the washout time between natalizumab and fingolimod

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1248-

  De Seze, Jérôme ^a,b   Ongagna, Jean Claude ^b   Collongues, Nicolas ^a,b   Zaenker, Christophe ^b   Courtois, Sylvie ^c   Fleury, Marie ^a,b   Benoilid, Aurélien ^a,b   Chanson, Jean Baptiste ^a,b   Blanc, Frédéric ^a,b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b Hôpitaux Universitaires de Strasbourg   (France)

^c HÔPITAL CIVIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; NATALIZUMAB;

DISEASE DURATION; DRUG SUBSTITUTION; EXPANDED DISABILITY STATUS SCALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; RELAPSE; SEX RATIO; THERAPY DELAY; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84881063695     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513490551     Document Type: Letter

References (5)

1. Baumgartner A, Stich O, Rauer S. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab. Int J Neurosci. 2012 ; 122: 35-39
2. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci. 2011 ; 308: 98-102
3. Daelman L, Maitrot A, Maarouf A, et al. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012 ; 18: 1647-1649
4. Jander S, Turowski B, Kieseier BC, et al. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler. 2012 ; 18: 1650-1652
5. Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: Clinical and magnetic resonance imaging findings. Mult Scler. 2012 ; 18: 1640-1643